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1 Abstract 
Potentially nonadentate (N5O4) bifunctional chelator p-SCN-Bn-
H4neunpa and its immunoconjugate H4neunpa-Trastuzumab for 111In 
radiolabeling are synthesized. The ability of p-SCN-Bn-H4neunpa and 
H4neunpa-Trastuzumab to radiolabel quantitatively 111InCl3 at ambient 
temperature within 15 min or 30 min, respectively, is presented. Ther-
modynamic stability determination with In3+, Bi3+ and La3+ resulted in 
high pM values. In vitro human serum stability assays have demon-
strated both 111In complexes to have high stability over 5 days. Mouse 
biodistribution of [111In][In(p-NO2-Bn-neunpa)]-, compared to that of 
[111In][In(p-NH2-Bn-CHX-A"-DTPA)]2-, at 1 h, 4 h and 24 h shows fast 
clearance of both complexes from the mice within 24 h. In a second 
mouse biodistribution study, the immunoconjugates 111In-neunpa-
Trastuzumab and 111In-CHX-A”-DTPA-Trastuzumab demonstrate a simi-
lar distribution profile, but with slightly lower tumor uptake of 111In-
neunpa-Trastuzumab compared to 111In-CHX-A”-DTPA-Trastuzumab. 
These results were also confirmed by Immuno-SPECT imaging in vivo. 
These initial investigations reveal the acyclic bifunctional chelator p-
SCN-Bn-H4neunpa to be a promising chelator for 111In (and other radio-
metals) with high in vitro stability, and also show H4neunpa-
Trastuzumab to be an excellent 111In chelator, with promising biodistri-




Early detection and specific therapy are the key factors for the 
successful treatment of cancer. 111In (t 1/2 = 2.8 days) and/or 177Lu (t 1/2 
= 6.6 days) are important radioisotopes in nuclear medicine that match 
either the requirements for single photon emission tomography 
(SPECT) and performing dosimetry, or for therapeutic purposes, respec-
tively. 111In being a cyclotron–produced radiometal (via the 
111Cd(p,n)111In reaction) emits gamma rays (245 and 171 keV) and Au-
ger electrons. 177Lu being a reactor-produced radiometal 
(176Lu(n,gamma)177Lu) emits primarily beta particles (490 keV) that can 
be used for therapy.1 
A common method to incorporate metallic radioisotopes (i.e. 
radiometals) into radiopharmaceuticals is via chelation of the desired 
radioisotope using a bifunctional chelator (BFC). As implied by the 
name, BFCs possess two properties – they must chelate the radiometal 
of interest in a tight and stable metal-ligand complex, and the BFC must 
incorporate a point of attachment for conjugation to a targeting vector 
(e.g. biomolecule of interest in disease progression such as a peptide 
or antibody). Both macrocyclic and acyclic chelators are used in the 
clinic, and are also of interest in the field of medicinal inorganic chem-
istry research. The pros and cons of cyclic vs acyclic chelators are 
widely known and beyond debate.2 Relevant to 111In and 177Lu, macro-
cyclic DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) 
is the gold-standard chelator, while acyclic chelator DTPA (diethylene-
triamine pentaacetic acid) and chiral analogue CHX-A”-DTPA are ubiq-
uitous in 111In radiopharmaceutical development (Figure 1). Recent 
studies developed bifunctional somatostatin analogues of DOTA with 
increased stability in vivo.3 As an acyclic gold-standard, the commer-
cially available radiopharmaceutical OctreoScan (111In-DTPA octeotride) 
reached approval in 1994 (Figure 1). Since the success of OctreoScan, 
several more bifunctional acyclic 111In chelators that contain different 
biomolecules have been developed, hoping to overcome the limitations 
of OctreoScan. These include an increased physiological uptake which 
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restricts the detection of small lesions, prolonged imaging protocol and 
relatively high radiation dose to the patients, as well as low image qual-
ity.4 
Our group has developed several promising acyclic chelators for 
111In and/or 177Lu, based on picolinic acid binding motifs, which we 
have since dubbed the “pa”-family of chelators.5-8 Of note, octadentate 
H4octapa (N4O4) and its bifunctional analogue p-SCN-Bn-H4octapa 
showed exceptional complexation properties (quantitative 111In or 177Lu 
radiolabeling in 10-30 minutes at ambient temperature) and favorable 
in vivo stability of resulting complexes.9,10 Furthermore, chiral ligands 
H2CHXdedpa (N4O2) and H4CHXoctapa (N4O4) showed promising 68Ga 
and 111In radiolabeling properties, respectively, and subsequently im-
pressive stability in human serum.8    
Our group continues to design ligands that may incorporate 
large metal ions (such as radioactive actinides/lanthanides for imag-
ing/therapy), which possess ideal properties for radiopharmaceutical 
incorporation, e.g. fast, mild, and quantitative complexation of radio-
metals at low ligand concentrations; formation of resultant thermody-
namically stable and kinetically inert metal-complexes; and a conven-
ient point of attachment to targeting vectors. Herein, we report the syn-
thesis and characterization of a novel nonadentate (CN = 9) acyclic 
chelator H4neunpa (N5O4, referred to herein as either p-NO2-Bn-
H4neunpa or H4neunpa) and bifunctional analogue p-SCN-Bn-H4neunpa 
that was designed as a bifunctional analogue of H5decapa (N5O5), re-
ported by our group in 2012.5 The carboxylic acid group on the middle 
nitrogen atom has been replaced by p-nitrobenzene-ethylene to keep its 
symmetry, and act as the bifunctional arm to attach the ligand to a bi-
omolecule through a thiourea bond (Figure 1). We hypothesized that 
the extended diethylenetriamine backbone and nine coordinating at-
oms of H4neunpa may favorably form complexes with large metal ions 
such as In3+ (92 pm, CN = 8)11, Lu3+ (103 pm, CN = 9), or Bi3+ (117 pm, 
CN = 8). Radiolabeling of 111In and 177Lu to H4neunpa was assessed and 
compared to gold-standards DOTA and CHX-A”-DTPA, and an in vivo 
biodistribution study of H4neunpa and CHX-A”-DTPA labeled with 111In 
was performed. Thermodynamic stability constants of selected metal-
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neunpa complexes were also determined. Moreover, coupling of the 
HER2/neu targeting monoclonal antibody (mAb) Trastuzumab was per-
formed via the reaction between the antibody’s primary-amine(s) with 
the isothiocyanate functional group of p-SCN-Bn-H4neunpa. The bio-
conjugate was labeled with 111In, and in vivo biodistribution and 
SPECT/CT imaging studies were conducted and compared directly to a 




Figure  1.  Structures of cyclic (DOTA) and acyclic (OctreoScan, CHX-A"-DTPA) com-
mercial chelators, and acyclic “pa”-ligands H2CHXdedpa, H4CHXoctapa, H4octapa, 
H5decapa, and novel nonadentate chelator p-SCN-Bn-H4neunpa discussed in this work.  
3 Results and Discussion 
3.1 Synthesis and characterization of the ligand 
The synthesis of the previously reported analogue H5decapa 
used N-benzyl protection, N-alkylation with an alkyl halide, benzyl 
deprotection via hydrogenation, a second alkyl halide N-alkylation, and 
finally deprotection in refluxing HCl (6M).10 The N-benzyl protection was 
found to be the yield-limiting step because the deprotection always 
resulted in partly eliminating the picolinic acid moieties. The use of O-
nitrobenzenesulfonyl (nosyl) was found to give better cumulative yields 





















































































logue H4neunpa, was synthesized with a general reaction scheme that 
follows N-nosyl-protection, bifunctionalization on the middle nitrogen 
atom via N-alkylation, N-alkylation with picolinic acid, nosyl-
deprotection with thiophenol, a second alkyl halide N-alkylation and 
ester-deprotection with LiOH to yield p-NO2-Bn-H4neunpa 6 (Scheme 1). 
The isothiocyanate (NCS) analogue for mAb conjugation, p-SCN-Bn-
H4neunpa 9, was synthesized from the intermediate 5 followed by nitro-
reduction, ester-deprotection with LiOH and isothiocyanate formation 
with thiophosgene (Scheme 1).  
Starting from the diethylenetriamine backbone, the two primary 
amines were protected with the 2-nitrobenzenesulfonyl groups to yield 
compound 1. Compound 1 is highly polar due to the two nosyl groups, 
thus a highly polar solvent like methanol is needed to separate it from 
the column. The second step is N-alkylation with 4-(2-
bromoethyl)nitrobenzene. In order to maintain symmetry of the ligand, 
the ideal spot for bifunctionalization is the middle nitrogen. After that, 
N-alkylation with methyl-6-bromomethyl picolinate5 was performed to 
yield compound 3. The most challenging step was the nosyl-
deprotection, constantly resulting in low yields of compound 4. The 
deprotected product is unfortunately highly polar and likely adsorbs on 
the surface of potassium carbonate, as seen by the red color of the 
salt. It was not possible to remove the large fractions of the deprotect-
ed product completely from the salt, which explains the low yield re-
ported in the Experimental Section. Subsequently, alkyl halide N-
alkylation was performed to yield product 5 with 71 % yield. p-NO2-Bn-
H4neunpa 6 was synthesized in a final step of ester deprotection with 
LiOH. This compound was further used for radiolabeling experiments 
as well as potentiometric stability titrations. The 1H NMR spectrum of 
the final product is shown in Figure 2. 
p-SCN-Bn-H4neunpa 9 was synthesized starting from the inter-
mediate 5 of the previous reaction route. Reduction of the nitro group 
with palladium on carbon yielded the amine-functionalized product 7.  
The hydrolysis of the two tert-butyl esters and two methyl esters was 
performed differently from previous reports.5,12 Instead of acidic hy-
drolysis at high temperatures, compound 8 was synthesized by adding 
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10 eq. of lithium hydroxide to the reaction mixture at room temperature 
to yield the product, with a 50 % yield. The final step is the synthesis of 
the isothiocyanate-functionalized product 9. This was achieved by the 
reaction of excess thiophosgene with the aromatic primary amine to 
yield the final product with a 59 % yield. Overall, the synthesis of p-SCN-
Bn-H4neunpa from diethylenetriamine has a cumulative yield of 2.3 %, 
comparable to the overall synthesis yield of H5decapa (2.5 %).  
 
















































































































3.2 Synthesis and characterization of non-radioactive metal com-
plexes 
3.2.1 NMR 
Three complexation experiments were performed with La3+, In3+ 
and Bi3+. 1H NMR spectra of the p-NO2-Bn-H4neunpa ligand precursor, 
and corresponding La and In complexes can be found in Figure 2. The 
[La(p-NO2-Bn-neunpa)]- complex shows 1H NMR upfield shifts of the 
alkyl-region; this effect has been previously observed in our group.13 
The aromatic region is more resolved and shows a splitting of the 
peaks. Integration of all peaks gives the same number of protons com-
pared to the uncomplexed ligand. Furthermore, the HSQC spectra of 
this complex (Figure S2) shows the same number of carbons compared 
to the bare ligand, suggesting that there is only one isomer in solution. 
In contrast, the 1H NMR spectrum of [In(p-NO2-Bn-neunpa)]- shows 
more splitting in the aromatic and alkyl regions. The aromatic peaks 
are sharp and well resolved and integrating the peaks suggests one 
major static isomer. In addition, the COSY spectrum of this complex 
shows clear coupling of several peaks in the complex alkyl region (Fig-
ure S12), leading to the assumption there are fluxional isomers in solu-
tion. Comparing these results to those with [In(decapa)]2-, which gave a 
complex 1H NMR spectrum with multiple isomers presumably due to 
several unbound carboxylates10, we can see an improvement in terms 
of isomerization by replacing one carboxylate group with the function-
alization arm on the middle nitrogen atom of the diethylenetriamine 
backbone. Due to insolubility of the Bi complex, the 1H NMR spectrum 




Figure  2.  1H NMR spectra of A: p-NO2-Bn-H4neunpa (400 MHz, CDCl3, 25 °C); B: [La(p-
NO2-Bn-neunpa)]
- (400 MHz, CDCl3, 25 °C); C: [In(p-NO2-Bn-neunpa)]
- (400 MHz, DMSO-
d6, 25 °C).  
 
3.2.2 IR 
Due to the insolubility of [Bi(p-NO2-Bn-neunpa)]-, an IR experi-
ment on the solid was performed (Figure 3). Shifts of various peaks of 
the ligand itself compared to the Bi complex can be observed. The OH 
stretch at 2500 cm-1 disappeared after complexation, suggesting that 
the carboxylic acids are bound to the metal ion; the carboxyl stretch at 
1700 cm-1 disappeared as well, supporting this assumption. The two 
stretches of the nitro functional group (1500 cm-1 and 1400 cm-1) 
stayed the same. The stretch at 1200 cm-1 in the ligand spectra can be 
assigned as a C-N stretch that shifts to lower energies (1000 cm-1) 





























Figure  3.  IR spectra of p-NO2-Bn-H4neunpa and [Bi(p-NO2-Bn-neunpa)]
-. 
 
3.2.3 Thermodynamic Stability 
The extended diethylenetriamine backbone, along with the non-
adentate N5O4 binding motif of H4neunpa, were specifically designed to 
accommodate binding of larger metal ions. As such, the protonation 
constants of H4neunpa as well as the stability constants of the respec-
tive La3+, Bi3+ and In3+ complexes were determined at 25 ºC in 0.16 M 
NaCl aqueous solution. The stepwise protonation constants (log K) 
obtained are presented in Table 1 together with protonation and stabil-
ity constants reported for the related ligands H5decapa, H4octapa, 
DTPA and CHX-A”-DTPA. A straightforward comparison of the ability of 
different ligands to coordinate a specific metal ion (rather than the 
thermodynamic stability constants alone) is the conditional stability 
constant or pM value. pM is defined as (-log [Mn+]free) and is calculated 
at specific conditions ( [Mn+] = 1 µM, [Lx-] = 10 µM, pH 7.4 and 25 ºC), 
taking into consideration both metal-ligand association and ligand ba-
sicity. The protonation constants of the new synthesized ligand 
H4neunpa were determined by potentiometric titrations at pH 1.8-11.5 
and by combined potentiometric-spectrophotometric titrations16,17 over 
























  Table  1.  Stepwise Protonation Constants (log KHhL) of H4neunpa (25 ºC, I = 0.16 M 
NaCl)a 
a Literature data of related systems are presented for comparison. L = Ligand and 
charges of ligand species and metal complexes were omitted for simplicity. 
In Figure S3 are shown the sets of spectra obtained as a func-
tion of pH, at 7.18 x 10-4 M ligand concentration. The first and second 
protonation processes occur at the two terminal amines of the diethy-
lenetriamine backbone (log K1 = 10.92(2) and log K2 = 9.29(2)), as sug-
gested by the appearance of a single isosbestic point at 284 nm be-
tween pH 8.33 and 11.32 in the UV-potentiometric titration (Figure 
S3c). The third protonation process (log K3 = 6.79(2)) is assigned to the 
central nitrogen atom in the backbone and is supported by the appear-
ance of an isosbestic point at 293 nm in the pH region between 5.39 
and 8.33 (Figure S3b). The fourth and fifth protonation processes are 
attributed to the picolinate moieties13,18  (log K4 = 4.02(3) and log K5 = 
2.97(2)). The UV-potentiometric titration showed also in this case a 
single isosbestic point at 296 nm for these protonation processes (Fig-













L + H+ ⇆ HL 10.92(2) 11.03(3) 8.59(4)  11.84 12.30 12.60(1) 
HL + H+ ⇆ H2L 9.29(2) 9.20(3) 5.59(6)  9.40 9.24 9.70(1) 
H2L + H+ ⇆ H3L 6.79(2) 6.86(4) 3.77(2) 4.85 5.23 4.50(1) 
H3L + H+ ⇆ H4L 4.02(3) 4.43(4) 2.77(4) 3.10 3.32 4.14(1) 
H4L + H+ ⇆ H5L 2.97(2) 3.46(5) 2.79(4) 2.20 2.18 2.32(1) 
H5L + H+ ⇆ H6L 2.39(5) 2.84(6) ND 
   
H6L + H+ ⇆ H7L ND 2.52(4) 
    
H7L + H+ ⇆ H8L 
 
ND 
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acid substituent (log K6 = 2.39(5)) and was calculated from potentiom-
etric titrations. The value of log K7 could not be determined, as the val-
ue was below the threshold of the electrode (pH < 2). H4neunpa, the 
bifunctional analogue of the previously reported H5decapa (for which 
we correct here the protonation constants, Table 1) presents overall 
fairly similar protonation constants, although the fourth and fifth pro-
tonation processes attributed to the picolinate moieties differ by 0.41 
and 0.49 units respectively. The higher protonation constants in the 
case of H5decapa could be attributed to the higher negative charge of 
the ligand. The speciation plots for H4neunpa and H5decapa are shown 
in Figure S4 in the Supporting Information. 
Potentiometric titrations of H4neunpa were carried out in the 
presence of La3+, Bi3+, and In3+ in order to determine the stability con-
stants of the corresponding metal complexes. For lanthanum, com-
bined potentiometric-spectrophotometric titrations demonstrated that 
the complexation started from pH 2, based on the distinctive features 
of the spectra compared to the electronic spectra of H4neunpa (Figures 
S3 and S5). The thermodynamic stability of [La(neunpa)]- was deter-
mined to be log KML = 19.81(4) and pM = 16. This value is close to the 
values obtained for [La(octapa)]- log KML = 19.92(6)19 and [La(DTPA)]2- 
log KML = 19.4820. Similar to the free ligand, the deprotonation of the 
[La(H2neunpa)]+ and La(Hneunpa) species is marked by the appearance 
of a single isosbestic point at 291 nm between the pH range 2.42-8.23 
and suggests that the deprotonations occur at the two terminal amines 
of the diethylenetriamine backbone (Figure S5a). The [La(neunpa)]- 
species further deprotonates presumably due to the deprotonation of a 
coordinated water molecule with pK 9.78 to form the monohydroxo 
complexes (Figure S5b). Species distribution diagrams for the lantha-
num(III) complexes of H4neunpa are plotted in Figure S6. The thermo-
dynamic stability constant of the bismuth(III) complexes of H4neunpa 
could not be determined by direct potentiometric titrations as this re-
quires the knowledge of the concentration of the free and bound metal 
ion at equilibrium, and even at pH 2 the Bi(III) complex was already sig-
nificantly formed. The ligand-ligand competition method using 
Na2H2EDTA as a known competitor was used to yield the stability con-
	 49	
stants presented in Table 2 and speciation plots in Figure S7. Particu-
larly high thermodynamic stability of [Bi(neunpa)]- was found, log KML = 
28.76(9) and pBi = 27. The thermodynamic stability constant of the 
[Bi(neunpa)]- complex is lower than those of [Bi(DTPA)]2- and [Bi(CHX-A-
DTPA)]2- complexes14 and lower than that for [Bi(DOTA)]-; however, it is 
interesting to note that H4neunpa and DOTA have the same pBi3+ value 
of 27 (Table 2). 
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Table  2.   Stepwise Stability Constants (log K) of H4neunpa complexes with La
3+, Bi3+ and In3+ a 
equilibrium reaction neunpa4- decapa5- 10 octapa4- DTPA CHX-A’’-DTPA DOTA 
La3+ + L ⇆ LaL 19.81(4) 
 
19.92(6)19  19.4820 
 
22.021 
LaL + H+ ⇆ LaHL 8.05(5) 
     
LaHL + H+ ⇆ LaH2L 3.28(6) 
     
LaLOH + H+ ⇆ LaL 9.78(4) 
     
Bi3+ + L ⇆ BiL 28.76(9) 
  
35.2(4)14  34.9(4)14  30.322 
BiL + H+ ⇆ BiHL 10.26(5) 
     
BiHL + H+ ⇆ BiH2L 3.8(1) 
     
BiLOH + H+ ⇆ BiL 10.57(7) 
     
In3+ + L ⇆ InL 28.17(2) 27.56(5) 26.8(1)10  29.023,24 
 
23.9(1)24  
InL + H+ ⇆ InHL 5.07(2) 5.47(3) 2.9(2)10  
   
InHL + H+ ⇆ InH2L 3.40(3) 2.73(6) 
    




   
pBi3+ 27 
    
2725 
pIn3+ 23.6 23.1 26.510 25.710   18.810 
a Literature data for related systems are presented for comparison. L = Ligand and charges of ligand species and metal complexes 
were omitted for simplicity. 
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Despite the high formation constant of [In(H2neunpa)]2+ log 
KMLH2 = 36.64(3), the system is well determined by direct potentiometric 
titration taking advantage of the indium-chloride competing species. 
The system as in the case of lanthanum(III) and bismuth(III) complexes 
containing MLH2, MLH, ML and ML(OH) complex species (Figure S8) 
presented a high log KML = 28.17(2) and pM = 23.6, which is significant-
ly higher than for DOTA (Table 2), slightly higher than for the previously 
reported H5decapa, 2.1 pM units lower than for DTPA and 2.9 pM units 
lower than for [In(octapa)]-. To our knowledge thermodynamic for-
mation constants of the [In(CHX-A”-DTPA)]2- have not been yet report-
ed. It is noteworthy that, as with other previously reported ligands10, the 
trend of the stability constants and pM values and the human serum 
stability data do not correlate well, and despite the higher pM values for 
[In(octapa)]- species or [In(DTPA)]2- vs [In(neunpa)]-, [In(neunpa]- 
showed an exceptional serum stability 97.8(1) % after one day, 5.5 
units higher than the [In(octapa)]- complex, 7.9 units higher than the 
[In(CHX-A”-DTPA)]2- complex and 9.5 units higher than the [In(DTPA)]2- 
complex.  
 
3.3 Radiolabeling Experiments with Unmodified Chelators  
The radiolabeling properties of 177Lu and 111In with H4neunpa 
were investigated, and compared directly to results obtained for the 
gold-standards DOTA and CHX-A”-DTPA. 
Initial radiolabeling experiments revealed that p-NO2-Bn-
H4neunpa could quantitatively complex 111In3+ (radiochemical yield, 
RCY > 99%) in 10 minutes at room temperature (RT), pH 4, at ligand 
concentrations of 10-4 M. Subsequently, concentration-dependent label-
ing was performed by decreasing the ligand concentration 10-fold while 
keeping the 111In activity constant. Quantitative radiolabeling was 
achieved at ligand concentrations as low as 10-7 M (Figure 4), at 10 min 
and ambient temperature. At decreasing ligand concentrations of 10-8, 
10-9, and 10-10 M, radiochemical yields gradually decreased to 71.1, 
10.5, and 1.5%, respectively. These results demonstrate the ability of p-
NO2-Bn-H4neunpa to rapidly and efficiently complex 111In in high specif-
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ic activities at ambient temperatures. H4octapa showed similar radio-
labeling efficiencies at 10-7 M, results at lower ligand concentrations 
are not reported.10 In sharp contrast to the two “pa” ligands is the mac-
rocyclic gold-standard DOTA which is reported to require heating sam-
ples at 100°C for 30 minutes to achieve high radiochemical yields.10 
The acyclic chelator CHX-A”-DTPA is a relatively recent addition to the 
list of potential 111In chelators; in contrast to DOTA it can efficiently 
complex In3+ isotopes at ambient temperatures yet exhibits compara-
ble in vivo stability to DOTA conjugates2,26, making it a more appealing 
chelator for radiolabeling of heat-sensitive biomolecules such as af-
fibodies or antibodies.27-31 Our initial 111In radiolabeling studies with p-
NH2-Bn-CHX-A”-DTPA at ligand concentrations of 10-4 M corroborate 
the efficient and mild labeling of this ligand which yielded RCYs >99%; 
however, two evident peaks in the HPLC radio-chromatogram are ob-
served – one major product at 8.6 min and a minor product at 8.0 min 
(Figure S10), with the ratio between the major and minor product being 
7.7. The appearance of two distinct peaks in the radio-chromatogram 
may indicate the formation of distinct 111In-chelate isomers. Contrary to 
H4neunpa, at p-NH2-Bn-CHX-A”-DTPA concentrations of 10-7 and 10-8 M, 
111In labeling yield decreased to 75.0 and 3.4%, respectively. The ratio 
of major to minor product in the HPLC radio-chromatogram also 
changed drastically at lower ligand concentrations, with the ratio being 





Figure 4.  Radiolabeling results of 111In-p-NO2-Bn-neunpa (10min, RT, pH 4). 
Unlike the facile labeling kinetics of [111In(p-NO2-Bn-neunpa)]-, in-
itial radiolabeling studies with 177Lu were unsuccessful. Attempted 
177Lu labeling at ligand concentrations of 10-4 M in 10 minutes at room 
temperature, pH 4 or 5.5, displayed a radiochemical yield of 12.4%; 
heating the sample to 40 °C for 1 hour did not improve RCY. Conversely, 
gold-standard DOTA was quantitatively radiolabeled (RCY > 99%) with 
177Lu when heated to 40 °C for 1 hour at the same ligand concentration 
(10-4 M). The inability of p-NO2-Bn-H4neunpa to complex 177Lu isotopes 
at mild temperatures (< 40 °C) precluded further study with this isotope, 
since it was immediately obvious from the initial results that H4neunpa 
was a poor match for 177Lu and presented no potential advantage com-
pared to the gold-standard DOTA.  
 
3.4 Stability Studies with the Unmodified Chelators 
In order to probe the kinetic inertness of the [111In(p-NO2-Bn-
neunpa)]- complex, a 5 d in vitro competition experiment was performed 
in the presence of human blood serum. Serum contains many endoge-
nous ligands that can compete for In(III) binding in vivo, such as apo-
transferrin and albumin, and any chelate-bound 111In must therefore be 
sufficiently stable to withstand transchelation to such proteins. The in 
vitro stability of [111In(p-NO2-Bn-neunpa)]- at 1 h, 1 and 5 d time points 












was tested alongside gold-standard [111In(p-NH2-Bn-CHX-A”-DTPA)]2- for 
comparison (Table 3). The [111In(p-NO2-Bn-neunpa)]- complex exhibited 
exceptional stability, remaining 97.8% intact over 5 days, while the 
[111In(p-NH2-Bn-CHX-A”-DTPA)]2- complex showed an initial ~8% drop in 
stability after 1 h and subsequently stabilized for 5 days to remain 
90.1% intact. The initial drop in stability after 1 h may be due to the 
presence of two isomers in the labeling reaction of p-NH2-Bn-CHX-A”-
DTPA (vide supra, major isomer 88.5% and minor isomer 11.5%). Stud-
ies with 88Y-CHX-DTPA have demonstrated that thermodynamic stabil-
ity of the resultant metal complex can be significantly affected by the 
absolute configuration, possibly due to unfavourable steric hindrance 
of certain stereoisomers;32 therefore, it is feasible that the minor isomer 
is kinetically labile with respect to transchelation to serum proteins. 
Indeed, [111In(p-NO2-Bn-neunpa)]- displayed marginally higher stability 
than [111In(p-NH2-Bn-CHX-A”-DTPA)]2-, [111In(DOTA)]-, and [111In(octapa)]- 
after 1 d (97.8 ± 0.1%, 89.9 ± 0.6, 88.3 ± 2.2%, 92.3 ± 0.04%, respective-
ly).   
 
Table  3.  Human serum stability challenge data performed at 37°C  (n = 
3), with stability shown as percentage of intact 111In-complex. 
Complex 1 h (%) 1 d (%) 5 d (%) 
[111In(p-NO2-Bn-neunpa)]- 97.9 ± 0.3 97.8 ± 0.1 97.8 ± 0.7 
[111In(p-NH2-Bn-CHX-A”-DTPA)]2- 91.8 ± 1.8 89.9 ± 0.6 90.1 ± 0.9 
[111In(octapa)]- a 93.8 ± 3.6 92.3 ± 0.04 NDb 
[111In(DOTA)]- a 89.6 ± 2.1 88.3 ± 2.2 NDb 
111InCl3 (control) c 4.0 7.2 3.4 
a Mouse serum stability data performed at ambient temperature. b ND = not deter-
mined. c n = 1 only.; data included from ref10 for comparison 
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3.5 Initial Biodistribution Studies 
 Mouse biodistribution studies over the course of 24 
hours (n = 4 each time point) were performed with [111In(p-NO2-Bn-
neunpa)]- and [111In(p-NH2-Bn-CHX-A”-DTPA)]2- and the data are summa-
rized in Table 4. Both In-complexes were rapidly excreted through the 
kidneys and activity cleared quickly from all other organs. Notably, up-
take of [111In(p-NO2-Bn-neunpa)]- in the intestines was significantly 
higher than for [111In(p-NH2-Bn-CHX-A”-DTPA)]2- after 15 min (17.9 ± 
5.5% ID/g vs 3.6 ± 1.6% ID/g) and 1 h (39.8 ± 2.9% ID/g vs 10.7 ± 1.4% 
ID/g). One explanation for the difference in intestine uptake is that the 
mono-anionic 111In-neunpa complex is more lipophilic than the di-
anionic 111In-p-NH2-Bn-CHX-A”-DTPA complex, as evinced by shifts in 
the radio-HPLC retention times (tR = 12.9 min and 8.6 min, respectively) 
and the absolute logP values of each complex (-1.65 ± 0.04, and -3.85 ± 
0.17, respectively), thus shifting the excretion of the radiotracer from 
renal to intestinal elimination because highly charged polar substances 
are generally eliminated via the kidneys while less hydrophilic com-
pounds tend to be eliminated via the intestinal tract. Nonetheless, the 
remaining 111In-complex in the intestines at 1 h was rapidly excreted by 
4 h for both complexes, and the uptake in intestines of [111In(p-NO2-Bn-
neunpa)]- and [111In(p-NH2-Bn-CHX-A”-DTPA)]2- were no longer statisti-
cally different (p > 0.05) at later time points (0.265 ± 0.206% ID/g vs 
0.160 ± 0.047% ID/g, for 4 h; 0.216 ± 0.114% ID/g vs 0.129 ± 0.06% ID/g, 
for 24 h, respectively). It has been suggested that administration of an 
unstable 111In-complex would result in demetalation of the complex in 
vivo and subsequent accumulation of transchelated or “free” 111In3+ 
activity in the liver, spleen, and bone over time;33 therefore, the rapid 
excretion of [111In(p-NO2-Bn-neunpa)]-  and [111In(p-NH2-Bn-CHX-A”-
DTPA)]2- from these organs suggests both 111In-complexes are excep-
tionally robust and stable in vivo  (0.035 ± 0.008% ID/g vs. 0.023 ± 
0.006% ID/g for liver; 0.029 ± 0.01% ID/g vs 0.032 ± 0.008% ID/g for 
spleen; 0.010 ± 0.006% ID/g vs 0.007 ± 0.002% ID/g for bone, at 24 h, 
respectively). Furthermore, [111In(p-NO2-Bn-neunpa)]- had improved kid-
ney clearance compared to [111In(p-NH2-Bn-CHX-A”-DTPA)]2- at 24 h  
(0.077 ± 0.058% ID/g vs 0.301 ± 0.043% ID/g, respectively, p <0.05). 
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Although these initial biodistribution data appear promising it may be 
that the predicted -1 and -2 charge of the In-neunpa/-CHX-A”-DTPA 
complexes, respectively, at physiological pH, could be mediating the 










Table  4.   Decay corrected % ID/g values from biodistribution of 111In-complexes in healthy NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (4 months old), n = 4. 











Blood 1.979 (0.425)  0.077 (0.007)  0.022 (0.004)  0.0064 (0.0011)  
Fat 0.174 (0.113)  0.009 (0.001)  0.0020 (0.0009)  0.0009 (0.0007)  
Uterus 1.644 (0.321)  0.101 (0.011)  0.059 (0.072)  0.014 (0.005)  
Ovaries 0.983 (0.362)  0.056 (0.034)  0.012 (0.011)  0.0080 (0.0067)  
Intestine 17.941 (5.475)  39.760 (2.865)  0.265 (0.206)  0.216 (0.114)  
Spleen 0.792 (0.379)  0.073 (0.024)  0.032 (0.027)  0.029 (0.010)  
Liver 2.684 (0.190)  0.312 (0.090)  0.071 (0.016)  0.035 (0.008)  
Pancreas 0.287 (0.196)  0.026 (0.006)  0.010 (0.006)  0.0047 (0.0023)  
Stomach 1.251 (0.364)  0.054 (0.019)  0.012 (0.002)  0.062 (0.019)  
Adrenal glands 0.585 (0.089)  0.037 (0.029)  0.012 (0.010)  0.0009 (0.0018)  
Kidney 5.681 (1.343)  0.484 (0.322)  0.158 (0.105)  0.077 (0.058)  
Lungs 2.695 (0.392)  0.388 (0.526)  0.072 (0.101)  0.056 (0.096)  
Heart 0.419 (0.032)  0.075 (0.089)  0.011 (0.007)  0.0061 (0.0103)  
Muscle 0.394 (0.101)  0.016 (0.004)  0.0030 (0.0018)  0.0020 (0.0016)  
Bone 0.743 (0.351)  0.072 (0.029)  0.0099 (0.0069)  0.0102 (0.0060)  
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Brain 0.059 (0.033)  0.012 (0.002)  0.0013 (0.0006)  0.0009 (0.0016)  





2- Blood 2.370 (0.221)  0.091 (0.035)  0.013 (0.014)  0.0011 (0.0003)  
Fat 0.323 (0.070)  0.016 (0.007)  0.0037 (0.0014)  0.0024 (0.0017)  
Uterus 1.643 (0.121)  0.116 (0.045)  0.082 (0.092)  0.035 (0.007)  
Ovaries 1.279 (0.177)  0.077 (0.033)  0.024 (0.016)  0.0188 (0.0047)  
Intestine 3.644 (1.632)  10.713 (1.428)  0.160 (0.047)  0.129 (0.060)  
Spleen 0.627 (0.069)  0.074 (0.031)  0.036 (0.008)  0.032 (0.008)  
Liver 3.388 (0.293)  0.271 (0.093)  0.053 (0.005)  0.023 (0.006)  
Pancreas 0.539 (0.148)  0.036 (0.017)  0.014 (0.009)  0.0053 (0.0020)  
Stomach 1.037 (0.115)  0.058 (0.025)  0.018 (0.003)  0.042 (0.030)  
Adrenal glands 0.592 (0.174)  0.064 (0.048)  0.022 (0.003)  0.0156 (0.0043)  
Kidney 7.643 (1.741)  1.152 (0.276)  0.632 (0.076)  0.301 (0.043)  
Lungs 1.677 (0.227)  0.120 (0.045)  0.023 (0.003)  0.012 (0.002)  
Heart 0.697 (0.089)  0.041 (0.013)  0.011 (0.001)  0.0069 (0.0011)  
Muscle 0.500 (0.122)  0.022 (0.008)  0.0038 (0.0003)  0.0016 (0.0007)  
Bone 0.717 (0.187)  0.057 (0.011)  0.0112 (0.0014)  0.0066 (0.0015)  
Brain 0.063 (0.018)  0.017 (0.004)  0.0068 (0.0008)  0.0018 (0.0006)  
Tail 3.562 (1.334) 
 
0.349 (0.063)  0.410 (0.498)  0.0505 (0.0324)  
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tions and yield 
pH 6, r.t., 15 or 30 
min, 92.6 % 
pH 6, r.t., 30 min, 
91.6% 







Serum stability over 5 
days (%) 
94.7 % ND 
 
therefore, the In-complexes may not have ample opportunity to 
dissociate in vivo giving the appearance of a stable complex. 
In order to further scrutinize the in vivo stability of 111In-neunpa 
and 111In-CHX-A”-DTPA an immuno-conjugate should be prepared (vide 
infra) and accordingly, biodistribution of each complex can be moni-
tored over the course of several days instead of hours. 
 
3.6 Preparation of Bioconjugates and In Vitro Characterization 
The promising radiolabeling efficiencies and in vitro kinetic in-
ertness of [111In(p-NO2-Bn-neunpa)]- provided motivation to prepare and 
test the radiolabeling properties, and in vivo behaviour of the H4neunpa-
bioconjugate. The HER2/neu-targeting antibody Trastuzumab was 
chosen as the biovector because it is well established to target HER2-
expressing tumors such as the SKOV-3 ovarian cancer cell line. To pro-
vide a basis for comparison, the gold-standard CHX-A”-DTPA was also 
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conjugated to Trastuzumab and tested in parallel in the radiolabeling 
and in vivo experiments.  
The novel bifunctional chelator p-SCN-Bn-H4neunpa 9 and gold-
standard p-SCN-Bn-CHX-A”-DTPA were conjugated to Trastuzumab, by 
incubation at room temperature at 5:1 molar ratio of ligand to antibody 
under slightly basic conditions (pH 9.0).34 Final immunoconjugates 
were purified by spin filtration and stored at -20°C until use. A radio-
metric isotopic dilution assay was employed to determine the number 
of accessible chelates per antibody; an average of 5.5 ± 1.1 H4neunpa 
chelates per antibody and 4.6 ± 0.7 CHX-A”-DTPA chelates per antibody 
were conjugated to Trastuzumab.  
Preliminary 111In radiolabeling efficiency of H4neunpa-
Trastuzumab was tested at pH 5.0, 5.5, and 6.0 in NH4OAc buffer (0.15 
M) at RT, and the radiochemical yield (RCY) was assessed at 15 min. 
Calculated RCYs after 15 min were 15.0, 84.4, 92.6% at pH 5.0, 5.5, or 
6.0, respectively (Figure S11). RCY was also assessed after 90 min for 
pH 5.0 and 6.0 reactions; yields increased to 38% and remained con-
stant at 92% for pH 5.0 and 6.0, respectively. These initial radiolabeling 
tests suggest an optimal radiolabeling pH of 6.0 for H4neunpa-
Trastuzumab, in order to generate 111In-conjugates of high radiochemi-
cal yield (>90%) and purity in only 15 min at RT. This is in agreement 
with a solution equilibrium study, which reflects the maximum of the 
[In(neunpa)]- species formed at pH 6 (see distribution diagram in Figure 
S7). The kinetic inertness of 111In-neunpa-Trastuzumab was assessed 
in an in vitro human serum challenge assay at 37°C.  Much like the un-
conjugated precursor, 111In-neunpa-Trastuzumab was exceptionally 
inert to transchelation when incubated with human serum, with 95.0 ± 
1.1, 96.0 ± 2.5, 94.7 ± 0.6, and 94.8 ± 1.6% of the 111In-bioconjugate re-
maining intact after 1, 2, 5, and 7 days, respectively.  
111In-labeled Trastuzumab conjugates were then prepared for in 
vivo studies. Both immunoconjugates were radiolabeled with 111In in 
NH4OAc buffer (0.15 M, pH 6) for 30 min at RT (Table 5), resulting in 
exceptionally high radiochemical yields (>90%) and radiochemically 
pure products (>99% after spin purification) for both 111In-neunpa-
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Trastuzumab and 111In-CHX-A”-DTPA-Trastuzumab. Final specific activ-
ities were determined to be 28.0 and 20.8 mCi/mg (1036 and 770 
MBq/mg) for 111In-neunpa-Trastuzumab and 111In-CHX-A”-DTPA-
Trastuzumab, respectively. In vitro cellular binding assays with SKOV-3 
cancer cells showed both 111In-immunoconjugates absolutely reactive 
towards the tested cell line (>99% immunoreactivity). Both 111In-
immunoconjugates have thus the ability to still bind to HER2.  
 
3.7 Biodistribution and SPECT/CT Imaging Studies 
In order to compare directly the pharmacokinetics of 111In-
neunpa-Trastuzumab to 111In-CHX-A”-DTPA-Trastuzumab in vivo, biodis-
tribution and single photon emission computed tomography (SPECT) in 
conjunction with helical X-ray CT imaging experiments were performed 
on female mice bearing subcutaneous SKOV-3 ovarian cancer xeno-
grafts on the left shoulder. Either tracer was injected via the tail vein 
(~37 MBq, ~35 – 50 µg, in 200 µL saline), and after 1, 3, and 5 days (n = 
4 per time point) the mice were imaged (n = 2, Figure 4) and sacrificed 
to collect organs and tumors to be counted on a calibrated γ-counter.  
SPECT/CT overlays of 111In-CHX-A”-DTPA-Trastuzumab and 
111In-neunpa-Trastuzumab immunoconjugates are shown in Figure 5 at 
1, 3 and 5 days post injection. These images were corrected for decay 
to allow qualitative comparison for the two radiolabeled immunoconju-
gates. For 111In-CHX-A”-DTPA-Trastuzumab and 111In-neunpa-
Trastuzumab, day 1 images show significant activity in the blood, the 
heart, the spleen and the tumor. The activity in the blood, the heart and 
the spleen decreases over time. The 111In-CHX-A”-DTPA-Trastuzumab 
shows a higher activity in the tumor at all three time points, giving high-
ly localized activity to the tumor site. On the other hand, 111In-neunpa-
Trastuzumab shows a lower uptake of activity into the tumor at day 
one post injection. Over time, the activity in the tumor decreased to 
being barely visible after 5 days post injection. Activity in the tumors 
for the 111In-neunpa-Trastuzumab is still present at day 3 and 5 post-
injection but in order to be able to compare the two tracers, an appro-
priate scale bar was required to prevent oversaturation of the high up-
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take of the 111In-CHX-A”-DTPA-Trastuzumab within tumors. Reducing 
the max value of the scale bar by a factor of 2.8 shows the remaining 
activity within the tumors for the 111In-neunpa-Trastuzumab (data not 
shown). 
 
Figure 5.  SPECT/CT overlays of 111In-CHX-A”-DTPA-Trastuzumab (left) 
and 111In-neunpa-Trastuzumab immunoconjugates. Fused μSPECT/CT 
images in female mice with subcutaneous SKOV-3 xenografts on left 
shoulder, imaged at 1, 3 and 5 days post injection. Tumors are high-
lighted with arrows. 
 
Comparing the biodistribution pattern of 111In-neunpa-
Trastuzumab with 111In-CHX-A’’-DTPA-Trastuzumab, both tracer biocon-
jugates show the same general uptake profile, i.e. significant uptake in 
blood, spleen, liver, kidney, bone and tumor at day 1 (Figure 6 and Table 
S1). Three days and 5 days after immunoconjugate injection, the 
spleen and tumor still have the highest uptake of radiotracer compared 
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to all other organs, but with significant difference (p < 0.01) between 
111In-CHX-A”-DTPA-Trastuzumab and 111In-neunpa-Trastuzumab (49.65 
± 6.79 %ID/g for 111In-CHX-A’’-DTPA-Trastuzumab and 21.47 ± 6.61 
%ID/g for 111In-neunpa-Trastuzumab after 5 days in the spleen and 
59.14 ± 7.70 %ID/g for 111In-CHX-A’’-DTPA-Trastuzumab and 16.01 ± 
2.24 %ID/g for 111In-neunpa-Trastuzumab after 5 days in the tumor). 
This distribution of antibody-linked tracer is well known and is due to 
the metabolism and circulation of antibodies (or antibody-chelate con-
jugates).35  
   
 
Figure  6.  Biodistribution of 111In-CHX-A’’-DTPA-Trastuzumab compared 
to 111In-neunpa-Trastuzumab in specific organs. Data are expressed as 
mean ± SD (n=4). For statistical analysis * (p ≤ 0.05) and ** (p ≤ 0.01), 
two-way ANOVA. 
The blood, liver, kidney and bone show the lowest %ID/g regard-
ing all the different organs. The blood from 111In-neunpa-Trastuzumab 
treated mice is cleared faster than the gold-standard 111In-CHX-A’’-
DTPA-Trastuzumab between 1 d and 3 d. Additionally, 111In-CHX-A’’-
DTPA-Trastuzumab shows an increase in accumulation in the tumor 





















over time, whereas 111In-neunpa-Trastuzumab shows a decrease of 
uptake into the tumor over time, which is consistent with the SPECT/CT 
overlay observations. Regarding the tumor:organ ratios (Figure 7), 111In-
neunpa-Trastuzumab and 111In-CHX-A’’-DTPA-Trastuzumab show inter-
estingly only significant different values 5 d after injection for each 
ratio, tumor:blood, tumor:heart and tumor:muscle. Furthermore, the 
addition of the several chelating ligands onto Trastuzumab (5.5 ± 1.1 
H4neunpa chelates per antibody and 4.6 ± 0.7 CHX-A”-DTPA chelates 
per antibody) can modify the overall charge of the antibody. Specifical-
ly, one negative charge per [In(neunpa)]- complex and two negative 
charges per [In(CHX-A”-DTPA)]2- complex labeled to Trastuzumab is 
generated; this induces a two-fold increase of negative charge on the 
CHX-A”-DTPA-Trastuzumab conjugates compared to neunpa-
Trastuzumab conjugates, assuming an equal number of accessible 
chelates are occupied by In3+ in each immunoconjugate. Consequently, 
this variance in overall charge of the Trastuzumab conjugate might 
affect the biodistribution of the resultant 111In-tracer. The immunoreac-
tivity results are comparable for H4neunpa- and CHX-A”-DTPA-
Trastuzumab conjugates, showing that the reactivity between 
Trastuzumab and its receptor is not altered due to the structural modi-
fication post chelate-conjugation. We wonder if the stability of the 
Trastuzumab-receptor-complex might not be as stable because of the 
charge difference discussed before. This could lead to a decreased 
uptake into the cancer cells. To conclude from these observations, dif-
ferent pharmacokinetic mechanisms for 111In-neunpa-Trastuzumab and 
111In-CHX-A’’-DTPA-Trastuzumab might take place after 5 days. These 
differences will be investigated further in order to fully understand the 
mechanism of tumor uptake.  
The slightly inferior uptake for this radiometal-neunpa antibody 
conjugate is disappointing but the complete chemistry and biology 
results suggest strongly that H4neunpa is an attractive chelating ligand 
with a built In conjugatable moiety and should be investigated further 





Figure  7.  Tumor:Organ ratios of CHX-A’’-DTPA and neunpa. Data is 















































The acyclic chelator p-NO2-Bn-H4neunpa and the bioconjugated 
analogue H4neunpa-Trastuzumab (5.5 ± 1.1 chelates per antibody) 
have been synthesized, characterized (HR-ESI-MS, 1H NMR, 13C NMR, 
2D-HSQC and cold metal complexation studies) and evaluated via radi-
olabeling with 111In and 177Lu. Unfortunately, low radiochemical yields 
of p-NO2-Bn-H4neunpa with 177Lu were obtained (pH 4-5.5, ambient – 
40°C, max. RCY 12.4 %). The radiolabeling yields of p-NO2-Bn-H4neunpa 
and H4neunpa-Trastuzumab with 111In were a great success, >99 % and 
92.6 %, respectively. Human serum stability experiments revealed that 
the [111In(p-NO2-Bn-neunpa)]- complex and 111In-neunpa-Trastuzumab 
immunoconjugate were 97.8 and 94.7 % intact after 5 days, respective-
ly. H4neunpa-Trastuzumab was highly immunoreactive (>99 %) as indi-
cated by a cellular binding assay. Biodistribution study of [111In(p-NO2-
Bn-neunpa)]- in mice showed higher uptake into the intestine within the 
first hours compared to [111In(CHX-A”-DTPA)]2- due to its higher lipo-
philicity. Small animal SPECT/CT imaging and biodistribution studies 
of 111In-neunpa-Trastuzumab were performed using female NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ mice bearing SKOV-3 xenografts, and it was 
found that 111In-neunpa-Trastuzumab successfully identified the tumor 
from surrounding tissues and other organs. Compared to the gold-
standard 111In-CHX-A’’-DTPA-Trastuzumab, our immunoconjugate 
showed slightly lower tumor uptake which decreased over time and a 
lower tumor:blood ratio after 5 days post injection, although high quali-
ty SPECT/CT images were obtained. A different pharmacokinetic be-
havior of both immunoconjugates can be the result of different charges 
on the immunoconjugates. Thermodynamic stability experiments sup-
port these findings, since p-NO2-Bn-H4neunpa was found to bind strong-
ly to large, highly charged metal ions like In3+, La3+ and Bi3+. Indeed, the-
se results suggest H4neunpa as a strong Bi(III) chelator and, consider-
ing the higher 3.6 units pM value respect to its In(III) complex, it could 
be of interest for Bi(III) isotopes (212Bi and 213Bi) in targeted alpha ther-
apy (TAT). These encouraging results suggest H4neunpa and its im-
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munoconjugate have promise for studies with other radiometals and 
targeting vectors. These experiments are currently underway.  
 
5 Experimental 
Materials and Methods 
All solvents and reagents were from commercial sources (Sig-
ma Aldrich, TCI) and were used as received unless otherwise noted. p-
NH2-Bn-CHX-A”-DTPA and p-SCN-Bn-CHX-A”-DTPA were purchased 
from Macrocyclics (Dallas, TX) and used as received. Human serum 
was purchased frozen from Sigma Aldrich. 1H and 13C NMR spectra 
were recorded at room temperature on a Bruker AV400 instrument; the 
NMR spectra are expressed on the δ (ppm) scale and are referenced to 
the residual solvent signal of the deuterated solvent. All spectra were 
recorded with sweep widths of 0-14 ppm or -20-220 ppm for 1H and 13C 
NMR, respectively, and deviations in the presented spectra are magni-
fications for visualization purpose only. Assignments of the peaks in 
the NMR spectra are approximate. Mass spectrometry was performed 
on a Waters ZQ spectrometer equipped with an electrospray source. 
The HPLC system used for purification of ligands and precursors con-
sisted of a Waters 600 controller equipped with a Waters 2487 dual λ 
absorbance detector connected to a Phenomenex synergi hydro-RP 
80Å 250mm x 21.1 mm semi-preparative column. Analysis of 111In and 
177Lu radiolabeled chelate complexes was carried out using a Phenom-
enex Synergi 4 µ Hydro-RP 80 Å analytical column (250 mm x 4.60 mm 
4 µm) using an Agilent HPLC system equipped with a model 1200 qua-
ternary pump, a model 1200 UV absorbance detector (set at 250 nm), 
and a Raytest Gabi Star NaI(Tl) detector. The radiochemical purity and 
specific activity of the final 111In radioimmunoconjugates was deter-
mined by using a size-exclusion chromatography (SEC) column (Phe-
nomenex, BioSep-SEC-s-3000) on an Agilent HPLC system equipped 
with a model 1200 quaternary pump, a model 1200 UV absorbance de-
tector (set at 280 nm), and a Bioscan (Washington, DC) NaI scintillation 
detector (the radiodetector was connected to a Bioscan B-FC-1000 
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flow-count system, and the output from the Bioscan flow-count system 
was fed into an Agilent 35900E interface, which converted the analog 
signal to a digital signal). Instant thin layer chromatography paper 
strips impregnated with silica gel (iTLC-SG, Varian) were used to ana-
lyze crude 111In-immunoconjugate labeling reactions and complex sta-
bility and counted on either a BioScan System 200 imaging scanner 
equipped with a BioScan Autochanger 1000 or on a Raytest miniGita 
with Beta GMC detector radio-TLC plate reader using TLC control Mini 
Ginastar software. PD-10 desalting columns (Sephadex G-25 M, 50 kDa, 
GE Healthcare) and centrifugal filter units with a 50 kDa molecular 
weight cutoff (Ultracel-50: regenerated cellulose, Amicon Ultra 4 Cen-
trifugal Filtration Units, Millipore Corp.) were used for purification and 
concentration of antibody conjugates. 
 111InCl3 was cyclotron produced and provided by Nordion as a ~ 
0.05 M HCl solution. 177LuCl3 was purchased from Perkin-Elmer and 
provided as a solution in dilute HCl. 
 
Synthesis of compounds 
 N,N-(2-Nitrobenzensulfonamide)-1,2-triaminodiethane, 1 
Diethylenetriamine (4.19 mL, 38.8 mmol) was dissolved in THF 
(240 mL) and cooled to 0°C. Sodium carbonate Na2CO3 (9.04 g, 85.3 
mmol, 2.2 eq.) was added, followed by a slow addition of 2-
nitrobenzensulfonyl chloride (18.9 g, 85.3 mmol, 2.2 eq.), causing the 
reaction mixture to turn pale yellow. The reaction mixture was stirred 
overnight at room temperature. The off-white mixture was filtered to 
remove sodium carbonate and the filtrate was rotary evaporated to 
dryness. The crude product was purified by silica chromatography 
(CombiFlash Rf automated column system 220 g HP silica; solid 
(pause) preparation; A: hexanes, B: ethyl acetate, C: methanol, 100 % A 
to 100 % B gradient followed by 100 % C) to yield the product 1 as a 
yellow-orange solid (88 %, 16.15 g). 1H NMR (400 MHz, acetone-d6, 
25°C): 8.13-8.11 (m, 2H), 7.94-7.89 (m, 6H), 3.11 (t, J= 7.32 Hz, 4H), 2.67 
(t, J= 5.80 Hz, 4H). 13C NMR (101 MHz, acetone-d6, 25°C): 134.0, 132.7, 
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130.7, 125.0, 47.7, and 43.1. HR-ESI-MS calcd. for [C16H19N5O8S2+H]+: 




To a solution of 1 (16.15 g, 34.1 mmol) in DMF (60 mL) was 
added K2CO3 (6.13 g, 44.3 mmol, 1.3 eq.) and 4-(2-
bromoethyl)nitrobenzene (10.20 g, 44.3 mmol, 1.3 eq.). After stirring the 
reaction mixture for 3 days at 40°C, the bright yellow solution was 
cooled to room temperature and the excess K2CO3 was removed by 
centrifugation. After drying the solution in vacuo, the crude dark red 
product was purified by silica chromatography (Combi Flash Rf auto-
mated column system; 80 g HP silica; solid (pause) preparation; A: 
hexane, B: ethyl acetate, 100% A to 100% B gradient) to yield product 2 
as an orange fluffy solid (64.0 %, 13.59 g). 1H NMR (400 MHz, CDCl3, 
25°C): 8.11-8.09 (d, J= 8.58 Hz, 2H), 8.08-8.06 (m, 2H), 7.84-7.81 (m, 2H), 
7.76-7.73 (m, 4H), 7.32-7.30 (d, d= 8.58 Hz, 2H), 5.68 (s, 2H, NH), 3.07-
3.05 (t, d= 5.63, 4H), 2.86-2.82 (t, J= 6.88, 2H), 2.74-2.72 (m, 2H), 2.70-
2.67 (t, J= 6.62 Hz, 4H). 13C NMR (101 MHz, CDCl3, 25°C): 158.0, 157.6, 
147.5, 146.8, 129.6, 129.5, 124.0, 117.3, 114.4, 55.0, 52.5, 37.6, and 33.5. 






To a solution of 2 (13.59 g, 21.8 mmol) in dry DMF (80 mL) was 
added methyl-6-bromomethyl picolinate (11.55 g, 50.2 mmol, 2.3 eq) 
and sodium carbonate (5.32 g, 50.2 mmol, 2.3 eq). The bright orange 
reaction mixture was stirred at 60°C overnight, filtered to remove ex-
cess sodium carbonate, and concentrated in vacuo. The crude product 
was purified by silica chromatography (CombiFlash Rf automated col-
umn system; 2 x 80 g silica; solid (pause) preparation; A: hexane, B: 
ethyl acetate, 100% A to 100% B gradient) to yield product 3 as an or-
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ange/brown oil (70 %, 14 g). 1H NMR (400 MHz, CDCl3, 25°C): 8.02-8.00 
(m, 4H), 7.96 (d, J = 7.7 Hz, 2H), 7.78 (t, J = 7.8 Hz, 2H), 7.67-7.60 (m, 
6H), 7.54 (d, J = 7.8 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 4.67 (s, 4H), 3.89 (s, 
6H), 3.29 (t, J = 6.8 Hz, 4H), 2.58-2.51 (m, 8H). 13C NMR (101 MHz, 
CDCl3, 25°C): 165.3, 157.0, 148.1, 147.6, 146.4, 138.1, 132.1, 129.7, 
126.0, 125.9, 124.4, 124.4, 123.5, 55.3, 53.9, 52.9, 52.7, 46.9, and 33.4. 





To a solution of 3 (7.48 g, 8.1 mmol) in dry THF (100 mL) was 
added thiophenol (1.91 mL, 18.7 mmol, 2.3 eq.) and potassium car-
bonate (3.71g, 26.8 mmol, 3.3 eq.). The reaction mixture was stirred at 
50°C for 72 hours, changing color to light orange. The excess salts 
were removed by centrifugation (5 min, 4000 rpm) followed by several 
washes with DMF. The filtrate was concentrated in vacuo in a (maxi-
mum) 50°C waterbath temperature. The resulting crude dark orange oil 
was purified by neutral alumina chromatography (CombiFlash Rf au-
tomated column system; 6 x 40 g neutral alumina; liquid injection A: 
dichlormethane, B: methanol, 100 % A to 20 % B gradient) to yield prod-
uct 4 as an orange oil (32.4 %, 1.45 g). 1H NMR (400 MHz, CDCl3, 25°C): 
8.01 (d, J = 8.6 Hz, 2H), 7.90 (d, J = 7.6 Hz, 2H), 7.73 (t, J = 7.8 Hz, 2 H), 
7.45 (d, J = 7.7 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H), 3.99 (s, 4H), 3.91 (s, 6H), 
2.79-2.72 (m, 12H). 13C NMR (101 MHz, CDCl3, 25°C): 165.6, 158.9, 
148.6, 147.4, 164.4, 137.8, 129.7, 126.0, 123.9, 123.7, 55.9, 54.0, 53.0, 
52.7, 47.0, and 33.3. HR-ESI-MS calcd. for [C28H34N6O6+H]+: 551.2618; 





To a solution of 4 (1.45 g, 2.6 mmol) in acetonitrile (60 mL) was 
added tert-butylbromoacetate (894 µL, 6.1 mmol, 2.3 eq.) and sodium 
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carbonate (642 mg, 6.1 mmol, 2.3 eq.). The reaction mixture was stirred 
at 60°C overnight, filtered to remove excess sodium carbonate and 
concentrated in vacuo.  The crude product was purified by silica chro-
matography (CombiFlash Rf automated system; 40g HP silica; A: di-
chloromethane, B: methanol, 100% A to 20% B gradient) to yield product 
5 as an orange oil (72 %, 1.48 g). 1H NMR (400 MHz, CDCl3, 25°C): 8.11 
(d, J = 8.5 Hz, 2H), 8.03 (d, J = 7.7 Hz, 2H), 7.89 (t, J = 7.7 Hz, 2H), 7.52 
(d, J = 7.6 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 4.18 (s, 4H), 3.96 (s, 6H), 3.90 
(s, 4H), 3.73 (m, 2H), 3.54 (s, 4H), 3.45 (br s, 4H), 3.24 (m, 2H), 1.38 (s, 
18H). 13C NMR (101 MHz, CDCl3, 25°C): 168.7, 165.1, 156.7, 147.3, 
147.3, 143.8, 139.1, 130.1, 127.5, 125.0, 124.0, 83.2, 57.5, 56.0, 54.5, 
53.3, 50.4, 48.8, 29.8, 28.0. HR-ESI-MS calcd. for 
[C40H54N6O10H]+:779.3980; found 779.3973 [M+H]+. 
 
p-NO2-Bn-H4neunpa · 2.2 HCl · 3.1 H2O, 6 
To compound 5 (0.23 g, 0.3 mmol) in THF/H2O (3 mL, 3:1) was 
added lithium hydroxide (0.07 g, 3.0 mmol, 10 eq.) and the mixture was 
stirred for 16 h at room temperature. Solvents were evaporated and the 
crude product was purified by semi-preparative reverse-phase (RP) 
HPLC (10mL/ min, gradient A: 0.1% TFA in deionized water, B: acetoni-
trile, A: 95% to B: 100% for 25 min., tR= 14.00 min) and the product 6 
was obtained as a yellow oil (61 %, 0.12 g). 1H NMR (400 MHz, CDCl3, 
25°C): 8.11 (d, J = 8.5 Hz, 2H), 8.03 (d, J = 7.7 Hz, 2H), 7.89 (t, J = 7.7 Hz, 
2H), 7.52 (d, J = 7.6 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 4.18 (s, 4H), 3.90 (s, 
4H), 3.73 (m, 2H), 3.54 (s, 4H), 3.45 (br s, 4H), 3.24 (m, 2H). 13C NMR 
(101 MHz, CDCl3, 25°C): 168.7, 165.1, 156.7, 147.3, 147.3, 143.8, 139.1, 
130.1, 127.5, 125.0,124.0, 57.5, 56.0, 54.5, 48.8. HR-ESI-MS calcd. for 
[C30H34N6O10+H]+: 639.2415; found 639.2415 [M+H]+. Elemental analy-
sis: calcd % for p-NO2-Bn-H4neunpa · 2.2 HCl ·3.1 H2O: C 46.55 N 10.86 








Compound 5 (0.11 g, 0.1 mmol) was dissolved in glacial acetic 
acid (3 mL) and Pd/C 10% was added, the vessel sealed and purged 
with H2 gas, charged with a H2 balloon and left to stir for 2 h at room 
temperature. The reaction mixture was then filtered through Celite and 
concentrated under reduced pressure to yield compound 7. The aro-
matic amine was confirmed by a purple ninhydrin staining. The solution 
was filtered and the filtrate was concentrated in vacuo. 1H NMR (400 
MHz, MeOD, 25°C): 7.99 (m, 2H), 7.92 (t, J = 7.9 Hz, 2H), 7.62 (d, J = 7.7 
Hz, 2H), 6.87 (d, J = 7.9 Hz, 2H), 4.01 (s, 2H), 3.46 (br.4, 2H), 3.13 (m, 
4H), 2.79 (m, 4H), 1.41 (s, 18H). 13C NMR (400 MHz, MeOD): 172.3, 
166.7, 160.8, 148.3, 139.7, 139.5, 130.4, 128.3, 125.4, 125.2, 116.8, 82.7, 
59.4, 56.9, 53.4, 52.3, 50.6, 29.9, 28.4. HR-ESI-MS calcd. for 
[C40H56N6O8+H]+: 749.4238; found 749.4236 [M+H]+. 
 
p-NH2-Bn-H4neunpa, 8 
Compound 6 (0.09 g, 0.13 mmol) was dissolved in THF/H2O (3 
mL, 3:1) and lithium hydroxide (0.03 g, 1.26 mmol, 10 eq.) was added. 
The reaction mixture was left at room temperature for 24 hours. After 
product formation was confirmed by ESI-MS analysis, the solution was 
neutralized with 1 M HCl and solvents were concentrated in vacuo. For 
purification, semi-preperative RP-HPLC (10mL/ min, gradient A: 0.1% 
TFA in deionized water, B: acetonitrile, A: 95% to B: 100% for 25 min., 
tR= 11.50 min) was used and product 8 was obtained as a yellow oil 
(50 %, 0.04 g). 1H NMR (400 MHz, MeOD, 25°C): 8.05-8.04 (d, J = 6.6 Hz, 
2H), 7.96-7.94 (d, J = 5.8 Hz, 2H), 7.63-7.61 (d, J = 6.6 Hz, 2H), 7.42-7-40 
(d, J = 5.8 Hz, 2H), 7.32 (s, 2H), 4.08 (s, 4H), 3.71 (s, 4H), 3.59 (s, 2H), 
3.53 (s, 4H), 3.35 (s, 4H), 3.14 (m, 2H). 13C NMR (400 MHz, MeOD): 
173.5, 167.4, 159.0, 148.7, 140.3, 139.1, 131.8, 128.3, 125.6, 124.4, 
116.7, 58.7, 56.5, 55.8, 53.1, 50.1, 30.4; 13C-DEPT NMR (400 MHz, 
MeOD): 140.3↑, 131.5↑, 128.1↑, 125.6↑, 124.2↑, 58.4↓, 56.4↓, 55.5↓, 
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51.5↓, 49.9↓, 30.2↓. HR-ESI-MS calcd. for [C30H37N6O8+H]+: 609.2673; 




Compound 8 (0.04 g, 0.1 mmol) was dissolved in 0.1 M HCl (1 
mL) and dichloromethane (1 mL). Thiophosgene (0.05 mL, 0.6 mmol, 10 
eq) was added and the solution was stirred vigorously at room temper-
ature overnight in the dark. The solvents were concentrated in vacuo 
and the product purified by semi-preparative RP-HPLC (10mL/ min, 
gradient A: 0.1% TFA in deionized water, B: acetonitrile, A: 95% to B: 
100% for 25 min., tR= 17.00 min) to yield product 9 as an orange oil (59 
%, 0.02 g). 1H NMR (400 MHz, MeOD, 25°C): 8.04-8.02 (d, J = 6.7 Hz, 2H), 
7.95-7.92 (t, J = 8.2 Hz, 2H), 7.61-7.57 (t, J = 7.5 Hz, 2H), 7.27-7-25 (d, J 
= 7.5 Hz, 2H), 7.18-7.16 (d, J = 7.5 Hz, 2H), 4.05 (s, 4H), 3.66 (s, 4H), 3.55 
(s, 2H), 3.50 (s, 4H), 3.26 (br s, 4H), 3.07 (m, 2H). 13C NMR (400 MHz, 
MeOD): 173.5, 167.4, 159.0, 148.7, 140.3, 137.5, 131.5, 128.3, 126.9, 
125.6, 115.9, 58.7, 56.5, 55.8, 51.9, 50.1, 30.5; 13C-DEPT NMR (400 MHz, 
MeOD): 140.3↑, 131.4↑, 128.3↑, 126.9↑, 125.6↑, 58.7↓, 56.35↓, 56.5↓, 
51.9↓, 50.1↓, 30.5↓. HR-ESI-MS calcd. for [C31H35N6O8+H]+: 651.2237; 
found 651.2239 [M+H]+. 
 
Na[La(p-NO2-Bn-neunpa)]  
Compound 6 (10.2 mg, 16.0 mmol) was dissolved in water and 
lanthanum perchlorate (7.7 mg, 17.6 mmol, 1.1 eq.) was added. The pH 
was adjusted to 4 using 0.1 M NaOH. The successful La-complexation 
as a white precipitate was confirmed by HR-ESI-MS immediately after 
adding La(ClO)4. After centrifugation, the precipitate was washed with 
water. 1H NMR (400 MHz, DMSO-d6, 25°C): 8.15 (d, 2H), 8.01 (m, 2H), 
7.92 (m, 2H), 7.61 (d, J = 7.6 Hz, 2H), 7.50 (d, J = 8.5 Hz, 2H), 4.01 (s, 
4H), 3.69 (m, 5H), 3.51 (d, 4H), 3.25 (s, 7H). HSQC (400 MHz, DMSO-d6, 
25°C) in Supporting Information. HR-ESI-MS calcd. for [C30H32N6O10La]+: 




Compound 6 (20.3 mg, 31.8 mmol) was dissolved in water and 
bismuth trichloride (11.0 mg, 35.0 mmol, 1.1 eq.) was added. The pH 
was adjusted to 4 using 0.1 M NaOH. The successful Bi-complexation 
as a white precipitate was confirmed by HR-ESI-MS immediately after 
adding BiCl3. After centrifugation, the precipitate was washed with wa-
ter. The Bi-complex is not soluble in any solvent; DMSO-d6 was chosen 
for NMR analysis. 1H NMR and 13C NMR not measurable due to solubili-




In a 20 mL screw cap vial, compound 6 (12 mg, 0.019 mmol) 
was dissolved in H2O:MeOH (2:1, 1.5 mL). In a separate screw cap vial, 
[In(ClO4)3]·8H2O (32 mg) was dissolved in dist. water (0.5 mL) to make 
a stock solution (64 mg/mL). An aliquot (217 μL, 13.8 mg, 0.0249 
mmol) of this In(III) stock solution was added to the chelate solution. 
The pH of the solution was adjusted from pH 1 to pH 5 using 1 N NaOH 
and 0.1 M HCl. A stir bar was added, the reaction heated to 60°C in a 
sand bath and stirred for 3 hours with the lid loosely on. The mixture 
was removed from the heat and allowed to cool to room temperature. A 
white precipitate had formed, and the solution was then centrifuged 
and washed with dist. water (5 x 1 mL). After drying under high vacu-
um, the product as a white solid was collected (4 mg, 0.0053 mmol) 
with an overall yield of 28%. 1H, and COSY NMR (400 MHz, DMSO-d6) 
potential multiple isomers in solutions, see Figure S12 Supporting In-
formation. HR-ESI-MS calculated for [115InC30H30N6O10+H+Na]+: 
773.1038; found: 773.1039 (M+H+Na)+. 
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Bioconjugation of p-SCN-Bn-H4neunpa and p-SCN-Bn-CHX-A”-DTPA to 
Trastuzumab.  
Trastuzumab (Herceptin, Genentech, San Francisco, CA, USA) 
was purified using size exclusion columns (PD-10 desalting columns) 
and centrifugal filter units with a 50 kDa molecular weight cutoff and 
phosphate buffered saline (PBS, pH 7.4) to remove α-α-trehalose dehy-
drate, L-histidine, and polysorbate 20 additives. The purified antibody 
was brought up in PBS at pH 7.4. For each chelate-antibody conjuga-
tion, PBS (905 µL, pH adjusted to 9.0 using 0.1 M Na2CO3) and 
Trastuzumab (Genentech, San Francisco, CA, USA) (4 mg, 75 µL in PBS 
pH 7.4) was added to a low protein binding Eppendorf tube. To the an-
tibody mixture, 5 equivalents of p-SCN-Bn-H4neunpa or p-SCN-Bn-CHX-
A”-DTPA was added, respectively, in small portions (5 x 5 µL in DMSO). 
The reaction mixture was stirred at ambient temperature overnight, and 
subsequently purified by centrifugal filtration. The final bioconjugates 
were stored in 0.25 M sodium acetate at -20°C. Final protein concentra-
tion was determined by the Bradford assay. 
 
Chelate number – radiometric isotopic dilution assay.  
The number of accessible chelating ligands conjugated per an-
tibody was determined using previously described methods.36,37 Briefly, 
a 1 µCi/uL [111In]InCl3 working solution (non-radioactive In3+ spiked with 
111In) was prepared with a final In3+ concentration of 500 µM in ammo-
nium acetate buffer (0.15 M, pH 6). In duplicate, for each chelate-
antibody conjugate, 50 µg of bioconjugate (30 µL) was prepared into 
separate 1.5 mL Eppendorf tubes. Aliquots of 20, 25, and 30 µL of the 
[111In]InCl3 working solution were added to the two chelate-antibody 
samples. Positive controls containing 50 µg of bioconjugate and 25 µL 
of buffered 111InCl3 only (no non-radioactive In3+ added) were prepared 
in duplicate. Negative controls containing 30 µL of PBS, and 25 µL of 
[111In]InCl3 working solution were prepared in duplicate. Samples were 
allowed to incubate at room temperature overnight, after which time 
EDTA (50 mM, pH 5) was added at 1/9 of the reaction volume to scav-
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enge any unspecifically bound In3+, and incubated for 15 min. Each re-
action mixture was spotted onto iTLC-SG plates, and developed using 
EDTA (50 mM, pH 5) as mobile phase. Radioactivity on the plate was 
measured using a radio-TLC plate reader, and number of chelates at-
tached per antibody was calculated using equation (1). !"#$ !ℎ!"#$! =  # !!"#$% !" !"#$%&'$ (!!!!.!)!"!#$ # !"#$%& ×!"#$ !"!!     (1) 
111In-Chelate Radiolabeling Studies 
The ligand p-NO2-Bn-H4neunpa, or gold standard p-NH2-Bn-CHX-
A”-DTPA, was made up as a stock solution (1 mg/mL, ~10-3 M) in deion-
ized water. From this stock solution, serial dilutions were prepared to 
final ligand concentrations of 10-4 M – 10-9 M.  A 100 µL aliquot of each 
ligand stock (10-3 to 10-9 M) or water (blank control) was added to 
screw-cap mass spectrometry vials and diluted with sodium acetate 
buffer (pH 4, 10 mM, 880 µL). An aliquot of diluted 111In stock (20 µL, 
~200 µCi) was added to each vial and allowed to radiolabeled at ambi-
ent temperature for 10 min, then it was analyzed by RP-HPLC to con-
firm radiolabeling and calculate yields. For human serum stability stud-
ies, undiluted 111InCl3 stock (~20 µL, 5 mCi) was added to the reaction 
vial containing 10-4 M ligand in sodium acetate buffer. Areas under the 
peaks observed in the HPLC radio-trace were integrated to determine 
radiolabeling yields. Elution conditions used for RP-HPLC analysis were 
gradient: A: 0.1% trifluoroacetic acid (TFA) in water, B: acetonitrile; 0 to 
100% B linear gradient 20 min, 1 mL/min. [111In(p-NO2-Bn-neunpa)]- (tR = 
12.9 min), [111In(p-NH2-Bn-CHX-A”-DTPA)]2- (tR = 8.0 min (minor product); 
8.6 min (major product))  “111In3+” (tR = 5.3 min). 
 
Partition Coefficients 
111In-labeled complex (30 µL, 20 µCi) was diluted with phosphate 
buffered saline (pH 7.4, 470 µL), and added to 1-octanol (500 µL) in a 
1.5 mL Eppendorf tube. Samples were vortexed for 60 seconds and 
subsequently centrifuged to separate phases (3000 rpm, 5 min). Ali-
quots (490 µL) of the aqueous and organic phases were diluted in a 
standard volume (20 mL) of water or acetonitrile, respectively, for 
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measurement in an N-type Co-axial HPGe gamma spectrometer from 
Canberra fitted with a 0.5 mm beryllium window and calibrated (energy 
and efficiency) with a 20 mL 152Eu and 133Ba source. The samples were 
counted for a minimum of 5 minutes, with a dead time less than 5 %. 
The amount of 111In-complex  (Bq) in each fraction was quantified using 
the 171 and 245 keV gamma lines of 111In. 
  
111In-neunpa/CHX-A”-DTPA-Trastuzumab Radiolabeling for In Vivo 
Studies 
Aliquots of H4neunpa/CHX-A”-DTPA-Trastuzumab (650 µg) were 
diluted with ammonium acetate buffer (0.15 M, pH 6) such that the fi-
nal volume of the reaction was 1 mL, and then 111InCl3 (~20 mCi) was 
added. The mixtures were allowed to react at ambient temperature for 
40 min, and then analysed via iTLC-SG using 50 mM EDTA (pH 5) as 
eluent; 111In-labelled antibody remained at the baseline, while 111In3+ 
ions complexed as 111In-EDTA and eluted with the solvent front. Radio-
labeled immunoconjugates were then purified by PD-10 SEC columns 
and centrifugal filtration (50k cut-off). The radiochemical purity of the 
final radiolabeled bioconjugates was determined using SEC-HPLC (us-
ing an isocratic gradient of 0.1 M sodium phosphate monobasic dehy-
drate, 0.1 M sodium phosphate dibasic dodecahydrate, 0.1 M sodium 
azide and 0.15 M sodium chloride (pH 6.2-7.0)); the specific activity 
was calculated by injecting a known activity, and integrating areas un-
der the peaks of the UV-chromatogram measured against a standard 
curve.  
 
In Vitro Human Serum Stability Data  
The procedures of the serum competition studies followed 
closely those previously published.8,10 The compound [111In(p-NO2-Bn-
neunpa)]-, [111In(p-NH2-Bn-CHX-A”-DTPA)]2-, or blank control “111In3+” was 
prepared using the radiolabeling protocol as described above. In tripli-
cate for the 111In-complex, solutions were prepared in vials containing 
330 µL of 111In-complex (~1.6 mCi), 1000 µL of room temperature hu-
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man serum, and 670 µL of phosphate buffered saline (PBS, pH 7.4) and 
incubated at 37°C. At time points of 1 h, 1 and 5 days, 400, 400, and 800 
µL aliquots of the human serum competition mixture were removed 
from each vial, respectively, diluted to a total volume of 2.5 mL with 
PBS, and counted in a Capintec CRC-55tR dose calibrator; this value is 
recorded as “full activity” to be loaded onto the PD-10 column. The 2.5 
mL of reaction mixture was loaded onto a pre-conditioned PD-10 col-
umn, and the empty vial was counted again in the dose calibrator – this 
value was recorded as “residual activity” left in the vial. The loaded ef-
fluent was collected in a waste container, and then the PD-10 column 
was eluted with 3.5 mL of PBS, and collected into a separate vial. The 
eluent that contained 111In bound/associated with serum proteins (size 
exclusion for MW < 5000 Da) was counted in the dose calibrator and 
then compared to the total activity that was loaded onto the PD-10 col-
umn to obtain the percentage of 111In that was bound to serum proteins 
and therefore no longer chelate-bound by the relationship: 1 – (eluted 
activity/(full activity – residual activity) x 100. For serum stability of the 
radioimmunoconjugates, 111In-neunpa-Trastuzumab was first prepared 
as described above by incubating H4neunpa-Trastuzumab (200 µg) and 
111InCl3 (~1 mCi) in NH4OAc (0.15 M, pH 6) for 20 minutes at ambient 
temperature. After confirming a radiolabeling yield >95% via iTLC-SG in 
50 mM EDTA (pH 5), in triplicate, 111In-neunpa-Trastuzumab (330 µL, 
~320 µCi) was incubated with human serum (330 µL) and the mixture 
was left at 37°C for 168 h (7 d). At time points of 0, 1, 24, 48, 120, and 
168 h, aliquots (3 – 5 µL) of the competition mixture was spotted on 




The human ovarian adenocarcinoma HER2-positive SKOV-3 
cells were cultured at 37°C with 5% CO2 in Dulbecco's modified Eagle's 
medium (DMEM, LifeTechnologies, Rockford, IL, USA) containing 2 
mM glutamine and supplemented with 10% fetal bovine serum (Sigma-
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Aldrich, Oakville, ON, USA) and 100 U/mL of penicillin-streptomycin 
(LifeTechnologies). 
 
In Vitro Immunoreactivity Assay  
The immunoreactive fractions of 111In-neunpa-Trastuzumab and 
111In-CHX-A”-DTPA-Trastuzumab were determined according to the 
Lindmo cell-binding method38 using SKOV-3 cells37,39 as previously de-
scribed. Briefly, cells were suspended at 0.23 to 2.3 x 106 cells/mL in 
PBS (pH 7.4). For each tested antibody, 50 μL (from a solution of 0.45 
µg of each radioimmunoconjugate diluted in 5 mL of 1% PBS-BSA) was 
added to each cell concentration tube in duplicate. The radiolabeled 
immunoconjugates were incubated for 1 h at 37 °C and under gentle 
agitation. Cells were then pelleted and washed twice with PBS. Each 
cell-bound activity for the different cell conditions was determined by 
measuring the 111In amount of activity within the cell pellets using the 
Wallac WIZARD2 gamma counter with background and decay correc-
tion. The bound fraction was determined as a percentage of total add-
ed activity according to control samples. Immunoreactive fractions 
were estimated for conditions representing infinite antigen excess by 
linear regression analysis of a plot of total/bound activity against 
1/[cell concentration]. Results >80% were considered suitable for in 
vivo imaging.  
 
SKOV-3 Xenograft Mouse Models 
All experiments were conducted in accordance with the guide-
lines established by the Canadian Council on Animal Care and ap-
proved by the Animal Ethics Committee of the University of British Co-
lumbia (protocol # A16-0104). Female NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ mice (4 months old) obtained from an in-house breed-
ing colony were subcutaneously injected with 8 x 106 SKOV-3 cells in 
matrigel (BD Bioscience) on the left flank. 
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[111In(p-NO2-Bn-neunpa)]- and [111In(p-NH2-Bn-CHX-A”-DTPA)]2- in vivo 
Biodistribution 
[111In(p-NO2-Bn-neunpa)]- and [111In(p-NH2-Bn-CHX-A”-DTPA)]2- 
were prepared according to the radiolabeling protocol above using 10-4 
M ligand and ~ 148 MBq (~4 mCi) of 111InCl3 in sodium acetate buffer 
(10 mM, pH 4). Radiolabeling yields >99% were confirmed by RP-HPLC. 
Each radiolabeled tracer was diluted with PBS (pH 7.4) to a concentra-
tion of 10 MBq/mL (370 µCi/mL). Each mouse was intravenously in-
jected through the tail vein with ~ 1 MBq (100 µL) of the 111In complex 
and then sacrificed by inhalation of isoflurane followed by CO2 at 15 
min, 1 h, 4 h, or 24 h after injection (n = 4 at each time point). Blood was 
withdrawn by cardiac puncture and tissues of interest including fat, 
uterus, ovaries, intestine, spleen, liver, pancreas, stomach, adrenal 
glands, kidney, lungs, heart, muscle, bone (tibia), brain, and tail were 
harvested, washed in PBS, dried and weighed. Activity of each sample 
was measured by a calibrated gamma counter (Perkin Elmer, Wizard 2 
2480) with decay correction. The activity uptake was expressed as a 
percentage of the injected dose per gram of tissue (%ID/g). 
 
111In-neunpa/CHX-A”-DTPA-Trastuzumab SPECT/CT Imaging and Bio-
distribution Studies 
Mice with SKOV-3 ovarian cancer xenografts were administered 
with ~37 MBq (~1 mCi) of 111In-neunpa-trastuzmab (1.03 MBq/µg [28.0 
µCi/µg]) or 111In-CHX-A”-DTPA-Trastuzumab (0.77 MBq/µg [20.8 
µCi/µg]) in ~30 µL of PBS (pH 7.4) via tail vein injection. For each radio-
immunoconjugate, mice were imaged (n=2) at 1, 3, or 5 day after injec-
tion. Image acquisition and reconstruction was performed using the U-
SPECT-II/CT (MILabs, Utrecht, The Netherlands). Approximately 5 min 
prior to SPECT/CT image acquisition, mice were anesthetized via inha-
lation of 2% isoflurane/oxygen gas mixture and placed on the scanner 
bed. Anesthesia was maintained during imaging as well as body tem-
perature via a heating pad. A 5 min baseline CT scan was obtained for 
localization with voltage setting at 60 kV and current at 615 µA fol-
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lowed by a static emission scan using an ultra-high-resolution multi-
pinhole rat-mouse (1 mm pinhole size) collimator. Data were acquired 
in list mode, reconstructed using the U-SPECT II software and co-
registered for alignment.  SPECT images were reconstructed using 
maximum-likelihood expectation maximization (3 iterations), pixel-
based ordered subset expectation maximization (16 subsets) and a 
post-processing filter (Gaussian blurring) of 0.5 mm centered at pho-
topeaks 171 keV and 245 keV with a 20% window width.  Imaging data 
sets were decayed corrected to injection time and converted to DICOM 
data for visualization in the Inveon Research Workplace (Siemens Med-
ical Solutions USA, Inc.). As no calibration factor was used or attenua-
tion and scatter correction were performed on the images; they were 
used only for qualitative comparison between the two tracers and are 
presented using a min-max min-max scale bar of counts corrected for 
decay. For biodistribution studies, mice were sacrificed by inhalation of 
isoflurane followed by CO2 (n = 4 at each time point), blood was with-
drawn by cardiac puncture and tissues were collected and processed 
as described above. Tissues collected include all those listed above in 
addition to tumor tissue. 
 
Solution Thermodynamics 
Protonation constants and metal stability constants were calcu-
lated from potentiometric titrations using a Metrohm Titrando 809 
equipped with a Ross combined electrode and a Metrohm Dosino 800. 
The titration apparatus consisted of a 20 mL and 25 ºC thermostated 
glass cell and an inlet-outlet tube for nitrogen gas (purified through a 
10% NaOH solution) to exclude any CO2 prior and during the course of 
the titration. The electrode was daily calibrated in hydrogen ion con-
centrations using a standard HCl as described before13 in order to ob-
tain the calibration parameters E0 and pKw. Solutions were titrated with 
carbonate-free NaOH (0.157 M) that was standardized against freshly 
recrystallized potassium hydrogen phthalate. Protonation equilibria of 
the ligand were studied by titrations of a solution containing H4neunpa 
7.18 x 10-4 M at 25 ºC and 0.16 M NaCl ionic strength using a combined 
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potentiometric-spectrophotometric procedure.16,17 Spectra were rec-
orded in the 200–450 nm spectral range with a 0.2 cm path length fiber 
optic on a Varian Cary 60 UV/Vis Spectrophotometer. In the study of 
complex formation equilibria, the ligand-metal solutions were prepared 
by adding the atomic absorption (AA) standard metal ion solutions to a 
H4neunpa solution of known concentration in the 1:1 metal to ligand 
molar ratio. The exact amount of acid present in the lanthanum, bis-
muth and indium standards was determined by Gran’s method40 titrat-
ing equimolar solutions of either La(III), Bi(III) or In(III) and Na2H2-EDTA. 
Ligand and metal concentrations were in the range of 0.7-1.0 mM. Each 
titration consisted of 100-150 equilibrium points in the pH range 1.8-
11.5, equilibration times for titrations were 2 min for pKa titrations and 
up to 15 min for metal complex titrations. At least two replicate titra-
tions were performed for each individual system. Potentiometric data 
were processed using the Hyperquad2013 software41 while the ob-
tained spectrophotometric data were processed with the HypSpec.41 
Proton dissociation constants corresponding to hydrolysis of La(III), 
Bi(III) and In(III) aqueous ions and the indium-chloride stability con-
stants included in the calculations were taken from Baes and Mes-
mer.42 The overall equilibrium (formation) constants log β are referred 
to the overall equilibria: pM + qH + rL = MpHpLr (the charges are omit-
ted), where p might also be 0 in the case of protonation equilibria and q 
may be negative. Stepwise equilibrium constants log K correspond to 
the difference in log units between the overall constants of sequentially 
protonated (or hydroxide) species. The pM values for metal complexes 
were calculated by using the Hyss software43, from the set of stability 
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Figure S1.  1H NMR spectrum of Bi-p-NO2-Bn-neunpa complex ([Bi(6)]-, 




Figure  S2.  HSQC NMR spectra of p-NO2-Bn-H4neunpa (6) (top) (101 
MHz, 400 MHz, MeOD, 25 °C) and La-(p-NO2-Bn-neunpa) complex 

















Figure S3. a) UV spectroscopic titration of 7.18x10-4 M H4neunpa in 
0.16 M NaCl between pH 2.5 and 5.39 b) UV spectroscopic titration of 
7.18x10-4 M H4neunpa in 0.16 M NaCl between pH 5.39 and 8.33 c) UV 
spectrophotometric titration of 7.18x10-4 M H4neunpa in 0.16 M NaCl 
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Figure S4. a) Speciation plots for the H4neunpa ligand calculated with 
the protonation constants in Table 1, [H4neunpa] = 1.00 x 10-3 M, 25 °C 
and I = 0.16 M (NaCl). The dash lines indicate the fourth and fifth 
protonation processes. b) Speciation plots for the H5decapa ligand 
calculated with the protonation constants in Table 1, [H5decapa] = 1.00 
x 10-3 M, 25 °C and I = 0.16 M (NaCl). The solid lines indicate the fourth 
and fifth protonation processes for comparison with those of H4neunpa 
ligand. 
 
Figure S5. a) UV spectroscopic titration of 6.52x10-4 M H4neunpa and 
La3+ 1:1 metal to ligand molar ratio in 0.16 M NaCl between pH 2.42 and 
8.23 b) UV spectroscopic titration of 6.52x10-4 M H4neunpa and La3+ 
1:1 metal to ligand molar ratio in 0.16 M NaCl between pH 8.48 and 
10.54.  
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Figure S6. Speciation diagram for the La3+-H4neunpa system from 
potentiometric titrations. [La3+] = [H4neunpa] = 6.52 x 10-4 M, 25 °C and I 
= 0.16 M (NaCl). 
 
 




























































Figure S7. Speciation diagram for the Bi3+-H4neunpa system from 
potentiometric titrations. [Bi3+] = [H4neunpa] = 6.52 x 10-4 M, 25 °C and I 
= 0.16 M (NaCl). 
 
Figure S8. Speciation diagram for the In3+-H4neunpa system from 
potentiometric titrations. [In3+] = [H4neunpa] = 6.62 x 10-4 M, 25 °C and I 
= 0.16 M (NaCl). The dash line indicates the optimal pH for the 
radiolabeling of H4neunpa-trastuzumab. 
 
 





























Figure S9. RP-HPLC radiochromatograms of [111In(p-NO2-Bn-neunpa)]- 
labeled at ambient temperature, 10 minutes reaction time in sodium 
acetate buffer (10 mM, pH 4) and decreasing ligand concentration. 
 
Figure S10. RP-HPLC radiochromatograms of [111In(p-NH2-Bn-CHX-A”-
DTPA)]2- labeled at ambient temperature, 10 minutes reaction time in 
sodium acetate buffer (10 mM, pH 4) and 0.1 (top) or 100 µM (bottom) 
final ligand concentration. 
 
 
Figure S11. iTLC-SG radiotraces of 111In-neunpa-trastuzumab labeled at 
ambient temperature for 15 min, 200 µg of bioconjugate in ammonium 





Table S1. Biodistribution data of 111In-CHX-A”-DTPA-/neunpa-
trastuzumab performed over 5 days in mice bearing SKOV-3 ovarian 




Organ 1 d 3 d 5 d 1 d 3 d 5 d 
Blood 17.0 ± 
1.5 






3.2 ± 0.6 
Tumour 41.8 ± 
17.9 








Fat 0.6 ± 
0.1 






0.3 ± 0.1 
Uterus 15.4 ± 
3.2 






6.6 ± 1.1 
Ovaries 10.0 ± 
0.9 






6.7 ± 1.2 
Intestine 3.7 ± 
0.5 






2.3 ± 0.2 
Spleen 25.6 ± 
1.1 






22 ± 6.6 
Liver 8.9 ± 
1.0 







































1.1 ± 0.3 
Kidney 5.0 ± 
0.3 






4.3 ± 0.3 
Lungs 7.3 ± 
0.6 






2.4 ± 0.3 
Heart 4.7 ± 
0.4 






1.1 ± 0.1 
Muscle 0.9 ± 
0.1 






0.4 ± 0.1 




4.3 0.4 0.3 0.7 
Brain 0.3 ± 
0.04 








Tail 3.4 ± 
0.3 













Figure  S12.  COSY NMR spectra of In-(p-NO2-Bn-neunpa) complex (101 

























Figure S13.  Crude reaction mixture iTLC-SG radiotraces of 111In-
neunpa/CHX-A”-DTPA-trastuzumab prepared for in vivo studies labeled 
at ambient temperature for 30 min, 650 µg of bioconjugate in 
ammonium acetate buffer (0.15 M, pH 6), or 111In3+ control (no chelate-
antibody added); iTLC-SG developed in 50 mM EDTA (pH 5).  
 
